Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) is advancing its proprietary therapy, LUCID-MS, designed to address the underlying myelin damage in multiple sclerosis (MS), a disease affecting over 2.8 million people worldwide and approximately 1 million in the USA. The company announced the completion of Phase 1 clinical studies involving healthy volunteers, reporting that the therapy demonstrated a favorable safety profile and was generally well tolerated.
MS is a chronic autoimmune and neurodegenerative disease in which the immune system attacks myelin, the protective sheath surrounding nerve fibers in the brain and spinal cord. As myelin deteriorates, communication between nerves becomes disrupted, leading to symptoms that can include loss of mobility and bodily control. Current treatments often focus on reducing inflammation and relapse frequency but may not adequately address the underlying neurodegeneration and myelin damage that drive long-term disease progression.
Quantum BioPharma’s LUCID-MS program is built around the unmet need for MS therapies capable of directly protecting or restoring myelin integrity. The company reached a significant milestone in April 2026 when it announced the submission of an Investigational New Drug (IND) application to the U.S. Food and Drug Administration for LUCID-MS. This step moves the therapy closer to clinical testing in MS patients.
The advancement of LUCID-MS is important because it targets demyelination and provides neuroprotection, potentially offering a new approach to slow or halt disease progression. Many patients continue to experience worsening disability despite available immune-modulating therapies, highlighting the need for treatments that address neurodegeneration directly.
Quantum BioPharma’s progress could have significant implications for the MS community and the broader neurology field. If LUCID-MS proves effective in later-stage trials, it could become a cornerstone therapy for MS, potentially improving quality of life for millions and reducing the economic burden of the disease. The company’s focus on myelin repair distinguishes it from existing therapies and addresses a critical gap in MS treatment.
For more information, the latest news and updates relating to QNTM are available in the company’s newsroom at https://ibn.fm/QNTM. Forward-looking statements in this article involve risks and uncertainties, as detailed in the company's SEC filings, and should not be relied upon unduly.
